4-(2-(N-乙酰氨基)乙基)苯乙酮 | 23279-64-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(2-(N-乙酰氨基)乙基)苯乙酮
• 英文名称: N-[2-(4-acetylphenyl)ethyl]acetamide
• 英文别名: N-(4-acetyl-phenethyl)-acetamide；N-(4-Acetyl-phenaethyl)-acetamid；1-[4-(2-Acetamino-aethyl)-phenyl]-aethanon-(1)；4-(2-acetamidoethyl)-acetophenone
• CAS: 23279-64-3
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD02684182
• 分子量: 205.257
• InChiKey: MWPMMSVYHPAOIO-UHFFFAOYSA-N

物化性质

• 熔点：
  99-101 °C
• 沸点：
  214-216 °C(Press: 3 Torr)
• 密度：
  1.064±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-(N-乙酰氨基)乙基)苯乙酮 在 六氟异丙醇 、 六氟-2,3-双(三氟甲基)-2,3-二醇 、 盐酸羟胺 、 sodium acetate 、 2-(甲氧基羰基)苯硼酸 作用下， 以 硝基甲烷 、 乙醇 、 水 为溶剂， 反应 24.0h， 生成 4-<2-(acetamido)ethyl>-acetanilide
  参考文献：
  名称：

  在环境条件下使用硼酸/全氟频哪醇系统进行真正有机催化贝克曼重排的范围和机制

  摘要：

  羟基官能团的催化活化对于药物和商品化学品的生产具有重要意义。在这里，2-烷氧基羰基-和 2-苯氧基羰基-苯基硼酸被确定为在贝克曼重排中直接和化学选择性活化肟 N-OH 键的有效催化剂。这种经典的有机反应提供了一种独特的方法来制备官能化的酰胺产物，使用传统的羧酸和胺之间的酰胺偶联可能难以获得这些产物。在极性溶剂混合物中仅使用 5 mol% 的硼酸催化剂和全氟频哪醇作为添加剂，操作简单的方案具有条件温和、底物范围广和官能团耐受性高的特点。种类繁多的二芳基、芳基-烷基、杂芳基-烷基、和二烷基肟在环境条件下反应以提供高产率的酰胺产物。游离醇、酰胺、羧酸酯和许多其他官能团与反应条件相容。对催化循环的研究揭示了一种新型的硼诱导的肟酯交换，它提供了一种酰基肟中间体，参与了完全催化的非自蔓延贝克曼重排机制。酰基肟中间体独立制备并经受反应条件。它被发现是自给自足的；它反应迅速，单分子，不需要游离肟。一系列对照实验和

  DOI：

  10.1021/jacs.8b01618
• 作为产物：
  描述：

  乙酰溴 、 N-(2-苯乙基)乙酰胺 在 三氯化铝 、 1,1,2,2-四氯乙烷 作用下， 生成 4-(2-(N-乙酰氨基)乙基)苯乙酮
  参考文献：
  名称：

  Basic-alkyl Esters of p-(Aminoalkyl)-benzoic Acids. II

  摘要：

  DOI：

  10.1021/ja01252a036

文献信息

• Bita3 adrenergic receptor agonists and uses thereof
  申请人：——

  公开号：US20020052392A1

  公开（公告）日：2002-05-02

  The instant invention provides &bgr; 3 adrenergic receptor agonists of structural Formula (I), 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr; 3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供了结构式（I）的β3肾上腺素受体激动剂，其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐，其中Ar、R、R1、R2、R3、R4、R5、R6、R7、R8、X和Y的定义如本文所述。本发明还提供了在制备结构式（I）化合物中有用的中间体，结构式（I）化合物的组合，其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐与抗肥胖药物的组合；包括结构式（I）化合物、其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐的药物组合；或包括结构式（I）化合物、其立体异构体和前药，以及这些化合物、立体异构体和前药的药用盐，以及抗肥胖药物的药物组合的药物组合；以及治疗β3肾上腺素受体介导的疾病、症状或障碍的方法，该方法包括向哺乳动物施用结构式（I）化合物、其立体异构体或前药的有效量，或其药物组合；或者结构式（I）化合物、其药用盐、立体异构体或前药，以及抗肥胖药物的组合，或其药物组合。
• Beta3 adrenergic receptor agonists and uses thereof
  申请人：Pfizer Inc.

  公开号：US20030203913A1

  公开（公告）日：2003-10-30

  The instant invention provides &bgr; 3 adrenergic receptor agonists of structural Formula (I), 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr; 3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供结构式（I）的&bgr;3肾上腺素受体激动剂，其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，其中Ar、R、R1、R2、R3、R4、R5、R6、R7、R8、X和Y如所述。本发明还提供在制备式（I）化合物中有用的中间体，以及式（I）化合物的组合物，其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐与抗肥胖剂的组合物；以及包括式（I）化合物、其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐，或包括式（I）化合物、其立体异构体和前药，以及所述化合物、立体异构体和前药的药学上可接受的盐和抗肥胖剂的药物组合物。本发明还提供治疗哺乳动物&bgr;3肾上腺素受体介导的疾病、病况或障碍的方法，该方法包括向哺乳动物施用有效量的式（I）化合物、其立体异构体或前药，或其药物组合物；或者是式（I）化合物、其药学上可接受的盐、立体异构体或前药的组合物和抗肥胖剂，或其药物组合物的组合物。
• &bgr;3 adrenergic receptor agonists and uses thereof
  申请人：Pfizer Inc.

  公开号：US06566377B2

  公开（公告）日：2003-05-20

  The instant invention provides &bgr;3 adrenergic receptor agonists of structural Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating &bgr;3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.

  本发明提供了结构式（I）的β3肾上腺素受体激动剂，其立体异构体和前药，以及化合物的药物可接受的盐，立体异构体和前药的药物可接受的盐，其中Ar，R，R1，R2，R3，R4，R5，R6，R7，R8，X和Y如本文所定义。该发明还提供了在制备式（I）化合物中有用的中间体，与抗肥胖药物的式（I）化合物的组合，立体异构体和前药，以及化合物的药物可接受的盐，立体异构体和前药，以及包括式（I）的化合物的药物组合的制药组合物，立体异构体和前药，以及化合物的药物可接受的盐，立体异构体和前药，以及抗肥胖药物；以及治疗哺乳动物中β3肾上腺素受体介导的疾病，状况或障碍的方法，其中方法包括向哺乳动物施用式（I）化合物，其立体异构体或前药的有效量，或其药物组合物；或者是式（I）化合物，其药物可接受的盐，立体异构体或前药，以及抗肥胖药物的组合，或其药物组合物。
• Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity
  作者：Jennifer A. Lafontaine、Robert F. Day、Joe Dibrino、John R. Hadcock、Diane M. Hargrove、Michael Linhares、Kelly A. Martin、Tristan S. Maurer、Nancy A. Nardone、David A. Tess、Paul DaSilva-Jardine

  DOI：10.1016/j.bmcl.2007.06.072

  日期：2007.9

  A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human beta(3)-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the beta(3)-AR, functional selectivity against beta(1)- and beta(2)-ARs, and favorable pharmacokinetic profiles in vivo. Compound 17 increased oxygen consumption in rats, a measure of energy expenditure, with an EDO20% of 2 mg/kg. (c) 2007 Elsevier Ltd. All rights reserved.
• ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1326861A1

  公开（公告）日：2003-07-16